Status:

UNKNOWN

Efficacy of Adjunctive Tianeptine in the Treatment of Bipolar Depression

Lead Sponsor:

Hospital de Clinicas de Porto Alegre

Collaborating Sponsors:

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Stanley Medical Research Institute

Conditions:

Bipolar Disorder

Eligibility:

All Genders

18-70 years

Phase:

PHASE3

Brief Summary

One of the main challenges in the treatment of Bipolar Disorder (BD) is to achieve better functioning outcomes after syndromal recovery. Even treatment-responsive patients, who remain symptomatically ...

Detailed Description

One of the main challenges in the treatment of Bipolar Disorder (BD) is to achieve better functioning outcomes after syndromal recovery. Available treatments are reasonably effective in reducing acute...

Eligibility Criteria

Inclusion

  • To be included patients will be required to:
  • Meet DSM-IV criteria for bipolar disorder types I or II
  • Have current symptoms of depression, with a MADRS score over 12 at baseline
  • Have the capacity to consent to the study and comply with the study procedures
  • Use effective contraception in the case of women of childbearing age
  • Patients will need to be in a stable dose of mood stabilizer for at least one month prior to randomization.

Exclusion

  • Exclusion from the trial includes:
  • Patients with a well defined or suspected clinically unstable systemic medical conditions
  • Pregnant or lactating women
  • Patients who are currently taking augmentation medications or supplementation
  • Patients who do not tolerate the use of tianeptine
  • Inability to comply with either the requirements or informed consent of the treatment protocol.
  • Withdrawal criteria:
  • Withdrawal from the trial will take place whenever:
  • Patients stop taking medication or are deemed as non compliant by the attending physician
  • Patients stop taking contraceptives of become pregnant
  • Dose changes or additions/exclusions to existing medication - patients will be kept in the trial, but such changes will be computed as a primary outcome
  • Serious adverse reactions
  • Withdrawal of consent by the patient
  • Hospitalization

Key Trial Info

Start Date :

March 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2013

Estimated Enrollment :

13 Patients enrolled

Trial Details

Trial ID

NCT00879372

Start Date

March 1 2009

End Date

December 1 2013

Last Update

October 8 2013

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Hospital de Clinicas de Porto Alegre

Porto Alegre, Rio Grande do Sul, Brazil, 90035-003